Sensei Biotherapeutics net loss deepens to $170.2M on Faeth acquisition charges
Sensei Biotherapeutics (NASDAQ:SNSE) reported a significantly wider net loss for the first quarter of 2026, primarily driven by massive, one-time accounting charges stemming from its transformational acquisition of Faeth Therapeutics Inc. earlier in the year.










